Last updated: 2026-09-05 02:04:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Idexx Laboratories Inc. (IDXX) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $535,23, with a market capitalization of $42,46B and a P/E ratio of 36,59. Over the past 52 weeks, its price has ranged from $518,55 to $769,98. This page covers its latest market performance, valuation, price trends and company information.
$42,46B | |
$531,36 | |
$769,98 | |
$5,57 | |
$529,29 | |
289,82K | |
-- | |
36,59 | |
$769,98 | |
$518,55 | |
-- | |
-- |
Idexx Laboratories Inc. (IDXX) last closed at $529,29 as of 2026-09-05 00:00:00, unchanged from the previous close of $529,29.
During the latest regular trading session, IDXX traded between $5,57 and $769,98, with a volume of 289,82K shares. The closing price was near the upper end and near the lower end of its 52-week range.
Over the past seven days, Idexx Laboratories Inc. (IDXX) moved from $547,68 to $535,23, representing a decline of 2,27% ($12,45).
The stock traded between $522,50 and $536,06 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 498,88 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 6,6%
IDXX is currently trading at $535,23, placing it 6,6% of the way from its 52-week low of $518,55 to its 52-week high of $769,98. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 11000 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Idexx Laboratories Inc. (IDXX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.